Brain, Spine and Skull Base Cancer Program


The Deininger Lab has a long-standing interest in the biology and therapy of leukemia, specifically chronic myeloproliferative neoplasms (CMPN), including chronic myeloid leukemia (CML) and Philadelphia chromosome (Ph)-negative CMPN.

Dr. Paul Shami’s research efforts focus on developing novel therapies for acute myeloid leukemia and myelodysplastic syndromes. He focuses in his lab on drug discovery and drug development. Ongoing projects include the development of nitric oxide-delivering agents to treat AML, the development of dithiocarbamate/metal chelates to treat AML, and the development of CD33-targeted agents for the treatment of AML. Other research efforts include the study of the non-anticoagulant heparin ODSH in combination with chemotherapy for the treatment of AML as well as early phase trials for AML.